Psychosis in Parkinson's Disease

Area of Science:

• Neurology
• Psychiatry

Background:

• Psychotic symptoms are a frequent and challenging complication in Parkinson's disease (PD).
• PD-related psychosis typically manifests as visual hallucinations or delusions, frequently linked to antiparkinsonian medications.
• Risk factors include other medical conditions, psychoactive drugs, sleep issues, mood disorders, and cognitive decline.

Purpose of the Study:

• To highlight the importance of continuous monitoring for psychotic symptoms in PD patients.
• To outline comprehensive management strategies for PD-related psychosis.
• To emphasize the need for therapeutic regimen adjustments to optimize patient function.

Main Methods:

• Continuous patient monitoring for early detection of psychotic symptoms.
• Critical re-evaluation and adjustment of antiparkinsonian medication regimens.
• Management of comorbid medical conditions and psychoactive medications.
• Use of atypical antipsychotics, such as clozapine and quetiapine, for severe symptoms.
• Consideration of cholinesterase inhibitors for cognitive enhancement and psychosis reduction.

Main Results:

• Treatment strategies are tailored to the clinical presentation, ranging from reassurance for mild symptoms to hospitalization for severe agitation.
• Medication management is complex, balancing motor function with psychiatric symptom control.
• Clozapine and quetiapine are identified as safe and effective atypical antipsychotics for PD patients.
• Cholinesterase inhibitors show potential in improving cognition and reducing psychotic symptoms.

Conclusions:

• Proactive monitoring and individualized treatment are crucial for managing Parkinson's disease psychosis.
• A multidisciplinary approach is necessary, addressing medication adjustments, comorbidities, and specific psychiatric interventions.
• Optimizing treatment can improve motor, cognitive, and psychiatric outcomes in PD patients experiencing psychosis.